-

Diality Welcomes Ravi Parthasarathy as Chief Technology Officer

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.

Parthasarathy comes to Diality with decades of product development team leadership experience, most recently with ICU Medical, where he served as Vice President, Device Engineering. Prior to ICU Medical, he served in leadership and product development roles for Baxter Healthcare, Motorola, Siemens Medical Systems, and General Motors.

“We are delighted to welcome someone of Ravi’s expertise and passion to Diality,” said Osman Khawar, M.D., CEO of Diality. “Ravi’s wealth of experience leading development of innovative products and his alignment with Diality’s mission, vision, and values make him a perfect fit for Diality and our current and future product portfolios.” As Diality continues to evolve, Clayton Poppe will also assume the role of Chief Scientific Officer (CSO) where he will lead the company’s research, quality, and regulatory functions.

The Moda-flxTM Hemodialysis System is a patient-inspired hemodialysis system designed to empower healthcare professionals to choose what is best for patients, as well as their clinical practice.

“Diality’s mission of improving lives impacted by kidney disease resonates very strongly with me and is one of the many reasons I am excited to help develop the Moda-flxTM Hemodialysis System," said Mr. Parthasarathy. “Dialysis patients deserve more innovation to improve their quality of life and the quality of their care.”

About Diality

Headquartered in Irvine, Calif., Diality is a medical device company developing the Moda-flxTM Hemodialysis System. Diality’s hemodialysis system is currently not approved for sale in any region. To learn more, please visit www.diality.com, and find us on LinkedIn.

Contacts

Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Diality Inc.


Release Versions

Contacts

Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Social Media Profiles
More News From Diality Inc.

Diality Appoints Peter Donato as Chief Financial Officer

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. Donato joins Diality with nearly 35 years of financial leadership experience, including ove...

Diality Announces Three Poster Presentations During The American Society of Nephrology (ASN) Kidney Week 2025

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s Kidney Week 2025 in Houston, Texas. “Real-World Urea Clearance and Adequacy with the Moda-flx Hemodialysis System” proves the system’s ability to leverage 600mL/min dialysate flow rate to achieve weekly clearance and ultrafiltration targets from the standard three hemo...

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas. Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodia...
Back to Newsroom